Trial Profile
A Randomized, Double-blind, Parallel, Multicenter, Placebo-controlled, Prospective Study to Evaluate the Functionality of the Flushing ASsessment Tool (FAST) in Subjects Administered Niaspan [niacin] Plus Acetylsalicylic Acid (ASA), Niaspan Plus ASA Placebo or Niaspan Placebo Plus ASA Placebo Daily for Six Weeks.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 16 Oct 2009
Price :
$35
*
At a glance
- Drugs Niacin (Primary) ; Aspirin
- Indications Dyslipidaemias; Embolism and thrombosis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Abbott Laboratories
- 31 Aug 2009 Efficacy results presented at the Annual Congress of the European Society of Cardiology (ESC).
- 13 Jan 2009 Planned number of patients changed from 246 to 276 as reported by ClinicalTrials.gov.
- 13 Jan 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.